

Drug Delivery Platform Strategy

FOR IMMEDIATE RELEASE

16 June 2010

- Zodiac joint venture partner Stirling Products Limited targeting major pharma partnership
- Unique Commercial Opportunity

Zodiac Capital Limited (NSX: ZOD) ("Zodiac" or the "Company") is pleased to announce that its joint venture partner, Pharmaceutical and Healthcare group, Stirling Products Limited (ASX:STI) has released its commercialisation strategy for its breakthrough Inhalation Drug Delivery Platform.

With most major pharmas all facing dramatic loss of revenues as their respective blockbuster products come off patent during an extraordinary end of product cycle period, Stirling is well positioned to leverage its joint ventured Drug Delivery Platform.

Following the completion of the major design works that provides for the miniaturization of the desktop models to portable handheld devices, Stirling is now introducing its commercialisation approach to the market and to potential major partners.

Pulmonary delivery of drugs has long been acknowledged as a more efficient way of drug and vaccine delivery, however development of an optimal pulmonary delivery device has to date eluded the industry despite many hundreds of millions having been spent on delivery device development.

Stirling's device and patents address the shortcomings that industry has encountered and Stirling believes it is in a unique position that is unprecedented within the industry as the Stirling drug delivery device can uniquely provide for improved delivery of existing blockbusters – thereby enhancing the respective products and retaining their premium blockbuster value.

Stirling's Strategy Presentation follows:

ENDS



Australia
Phone +61 2 9299 9270
Fax +61 2 9299 9276

For further information contact:

Peter Boonen

Managing Director

Zodiac Capital Limited

Ph: +61 2 9299 9270

E: peter.boonen@zodiaccap.com

For all Investor Relations inquiries please contact:

James Moses

Mandate Corporate

Ph: +61 420 991 574

E: james@mandatecorporate.com.au